Mesoblast (MESO) Cash from Financing Activities (2016 - 2023)
Mesoblast (MESO) posted Cash from Financing Activities of $38.8 million for Q2 2023, up 1625.27% sequentially from -$2.5 million in Q1 2023, and up 1848.96% YoY from $2.0 million in Q2 2022.
Mesoblast (MESO) Cash from Financing Activities (2016 - 2023) Analysis & Trends
Mesoblast has reported Cash from Financing Activities for 8 years, with the latest figure at $38.8 million in Q2 2023.
- Quarterly Cash from Financing Activities rose 1848.96% year-over-year to $38.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $74.5 million (up 854.83% YoY) and the FY2025 annual result came in at $147.3 million, up 266.03% from the prior year.
- Cash from Financing Activities grew to $38.8 million in Q2 2023 per MESO's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $106.4 million in Q1 2021 and troughed at -$2.9 million in Q4 2021.
- A 5-year average of $17.8 million and a median of -$50500.0 in 2019 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2020 and 2021: Cash from Financing Activities jumped 251518.18% in 2020, then tumbled 294.22% in 2021.
- Over 5 years, Cash from Financing Activities stood at $48.2 million in 2019, then sank by 101.54% to -$744000.0 in 2020, then sank by 294.22% to -$2.9 million in 2021, then jumped by 31.4% to -$2.0 million in 2022, then soared by 2026.29% to $38.8 million in 2023.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $38.8 million, -$2.5 million, and -$2.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 38.76 Mn |
| Jun 30, 2023 | 38.76 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Sep 30, 2021 | -2.15 Mn |
| Sep 30, 2021 | -2.15 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Mar 31, 2021 | 106.36 Mn |
| Mar 31, 2021 | 106.36 Mn |